D30.02 refers to a non-malignant (benign) growth originating in the parenchymal tissues of the left kidney. Unlike malignant tumors such as renal cell carcinoma, these neoplasms do not metastasize to distant sites, though they may continue to grow locally and potentially interfere with renal function or adjacent anatomical structures. Common clinical entities categorized under this code include renal oncocytomas, which originate from the intercalated cells of the renal collecting ducts, and renal angiomyolipomas (AMLs), which are triphasic mesenchymal tumors composed of fat, smooth muscle, and dysplastic blood vessels. While many of these lesions are discovered incidentally on imaging (incidentalomas), larger benign tumors can lead to complications such as spontaneous retroperitoneal hemorrhage (Wunderlich syndrome), flank pain, or palpable abdominal masses. Accurate diagnosis is critical to distinguish these lesions from malignant renal cell carcinomas, as management ranges from active surveillance for small lesions to partial or total nephrectomy for symptomatic or large tumors.
Specify Histological Subtype and Confirmation Method
Example: Left renal mass identified as an 8 cm angiomyolipoma via CT scan with fat-containing density. Patient remains asymptomatic with no evidence of tuberous sclerosis. Planned for annual imaging surveillance. Benign nature documented to distinguish from C64.2 malignancy. Patient also has stable chronic hypertension managed with lisinopril.
Billing Focus: Identify histological type if known (e.g., oncocytoma vs. angiomyolipoma) to support medical necessity for specific surveillance intervals.
Document Laterality and Precise Anatomical Location
Example: A 2.4 cm benign oncocytoma is located in the left upper pole of the kidney. The mass is distinct from the renal pelvis (D30.12). No evidence of vascular invasion or lymphadenopathy. Documentation of the left side is essential for surgical planning if symptoms develop.
Billing Focus: Laterality (Left) must be explicitly stated to map to D30.02 rather than the non-specific D30.00.
Report Symptomatic Presentations or Incidental Findings
Example: Patient presents with dull left-sided flank pain; ultrasound reveals a 3.5 cm benign neoplasm of the left kidney. Urinalysis shows no hematuria. Pain is attributed to mass effect on the renal capsule. Monitoring renal function with serum creatinine due to mass location.
Billing Focus: Documenting associated symptoms like flank pain (R10.9) or hematuria (R31.9) justifies higher-level E/M visits and diagnostic imaging.
Include Relevant Comorbidities and Genetic Associations
Example: Benign neoplasm of left kidney (angiomyolipoma) in a patient with a known diagnosis of Tuberous Sclerosis (Q85.1). Blood pressure is monitored closely as the patient has secondary hypertension (I15.1) related to renal structural changes.
Billing Focus: Coding the genetic driver or secondary conditions (like hypertension) provides a complete picture of patient complexity.
Detail the Management and Surveillance Plan
Example: Stable 2.0 cm left renal oncocytoma. Review of prior MRI from 12 months ago shows no interval growth. Plan: Repeat renal ultrasound in 12 months. Patient advised on signs of retroperitoneal hemorrhage if mass exceeds 4 cm.
Billing Focus: Review of prior data and planning of future tests supports the Data and Risk columns for E/M leveling (e.g., 99214).
Used for routine follow-up of a stable benign kidney mass with no new symptoms and straightforward imaging review.
Appropriate when managing a symptomatic benign mass or one requiring complex management decisions, such as discussing surgical vs. non-surgical options.
The standard imaging modality for characterizing renal masses and distinguishing between benign and malignant features.
A common, lower-cost method for monitoring the size of known benign renal neoplasms.
The gold-standard surgical procedure for removing a benign but large or symptomatic neoplasm while preserving as much renal function as possible.
A minimally invasive option for treating small benign neoplasms in patients who are not candidates for surgery.
Provides superior soft tissue characterization, often used when CT findings are indeterminate for a benign vs. malignant lesion.
Standard for a new patient referral to a specialist for initial evaluation and diagnostic workup of a recently discovered renal mass.
Used for large benign tumors where partial nephrectomy is technically impossible or where total removal of the kidney is necessary.
Routine screening to check for microscopic hematuria or signs of renal damage associated with the neoplasm.